Truist Securities Downgrades BioXcel Therapeutics to Hold
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has downgraded BioXcel Therapeutics from Buy to Hold.

October 05, 2023 | 8:40 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioXcel Therapeutics has been downgraded from Buy to Hold by Truist Securities, which may impact investor sentiment and the stock's price.
Analyst ratings often influence investor sentiment and can impact a stock's price. A downgrade from Buy to Hold suggests that the analyst sees less upside potential in the stock, which could lead to selling pressure and a potential decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100